Edwards Lifesciences Reports Third Quarter Results

Go back to Edwards Lifesciences Reports Third Quarter Results

Edwards Lifesciences (EW) PT Raised to $122 at Oppenheimer

October 28, 2021 7:46 AM EDT

Oppenheimer analyst Suraj Kalia raised the price target on Edwards Lifesciences (NYSE: EW) to $122.00 (from $120.00) while maintaining an Outperform rating.

The analyst commented, "Edwards reported 3Q21 revenues of $1.31B, slightly behind our/consensus' $1.34B/$1.32B estimates, but within guidance of $1.291.37B. TAVR... More

Edwards Lifesciences (EW) PT Raised to $129 at Stifel

October 28, 2021 6:42 AM EDT

Stifel analyst Rick Wise raised the price target on Edwards Lifesciences (NYSE: EW) to $129.00 (from $120.00) while maintaining a Buy rating.

The analyst commented, "Despite pockets of OUS TAVR strength/recovery, US Covid impacts pushed 3Q21 revenues to $1.31B, just below Street... More

Edwards Lifesciences (EW) Reports In-Line Q3 EPS

October 27, 2021 4:17 PM EDT

Edwards Lifesciences (NYSE: EW) reported Q3 EPS of $0.54, in-line with the analyst estimate of $0.54. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.33 billion.

GUIDANCE:

Edwards Lifesciences sees Q4 2021 EPS of $0.53-$0.59, versus the consensus of $0.56.... More